Locus Biosciences is a biotechnology company whose mission is to protect humanity from the global threat of bacterial diseases. Locus uses its patented CRISPR Cas3-enhanced bacteriophage (crPhage™) platform to develop precision antibacterial products that selectively kill target bacteria while leaving non-targeted beneficial bacteria unharmed. With venture capital funding from ARTIS Ventures, Tencent Holdings, Abstract Ventures and others, Locus is rapidly advancing its lead programs into clinical development for infectious disease and large-market microbiome indications, with the first clinical trials on track to begin in 2019.